Members of the Texas Drug Utilization Review (DUR) Board meet quarterly in Austin to promote safety through an increased review and awareness of outpatient prescribed drugs. Members recommend medical criteria, standards, and educational intervention methods used in Texas Medicaid. The board reviews and approves the therapeutic criteria for prospective and retrospective drug utilization as well as clinical prior authorization criteria. In addition, members also recommend drugs for inclusion in the Medicaid preferred drug list, considering the drug's clinical efficacy, safety, cost-effectiveness, and program benefits.
Please review the written and public testimony procedures prior to submitting information to board members.
By Regular/Overnight Mail
Texas Drug Utilization Review Board (MC-2250)
Texas Health and Human Services
4900 North Lamar Blvd.
Austin, TX 78751
By Email
This address is only for issues pertaining to the Texas DUR board. Messages received off-cycle or unrelated to the business of the board are not accepted.
News
September 18, 2020
Branded Concerta Tablets Return to Non-Preferred Status on Oct. 16
September 14, 2020
Two-day DUR Board Meeting Scheduled for Oct. 22 and 23
September 14, 2020
Members Sought for the Drug Utilization Review Board
September 10, 2020
July 2020 Preferred Drug List Revised Sept. 8
September 9, 2020
Insulin Products Return to Non-Preferred Status on Sept. 18
September 4, 2020
Epidiolex and Diacomit Clinical Prior Authorization Criteria Updates
August 21, 2020
July 2020 Preferred Drug List Revised Aug. 21
August 11, 2020
July 2020 Drug Utilization Review Board Meeting Summary